Colorectal cancer (CRC) is a malignancy whose incidence is increasing globally, and there
is a gender difference in the increasing risk. Evidence from hormone replacement therapy …

A higher incidence of colorectal cancer (CRC) is found in males compared to females.
Young women (18–44 years) with CRC have a better survival outcome compared to men of …

Experimental studies have shown that estrogen-or progesterone-activated signaling leads to
growth inhibition effects on colon cancer cells through the upregulation of several cell-cycle …

Colon cancer (CRC) is a prevalent malignancy that exhibits distinct differences in incidence,
prognosis, and treatment responses between males and females. These disparities have …

Differences in morbidity rates between males and females have been reported for many
cancer sites. Specifically, in the colon, cancers in females are more commonly detected in …

Women consistently show lower incidence and mortality rates for colorectal cancer (CRC)
compared to men. Epidemiological evidence supports a pivotal role for estrogen in …

Introduction Sexual dimorphism significantly influences cancer incidence and prognosis.
Notably, females exhibit a lower risk and favorable prognosis for non-reproductive cancers …

Sex significantly influences the clinical and pathological characteristics of colorectal cancer
(CRC). These include differences in incidence and mortality rates, clinical presentations …

The incidence of colorectal cancer (CRC) shows a sex-dependent difference in humans.
The aim of this study was to analyze estrogen receptor β mRNA (ERβ) expression in patients …

Colorectal cancer (CRC) is one of the most common causes of cancer morbidity in both male
and female. The development of CRC is found 1.5 times higher in men compared to women …